Surrozen, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery and development of novel therapeutics that harness the Wnt signaling pathway. The company employs a proprietary “surrogate agonist” platform to engineer bispecific antibodies that mimic natural Wnt ligands by concurrently engaging Frizzled receptors and LRP5/6 co-receptors. This approach is designed to promote tissue regeneration and modulate cellular pathways implicated in fibrosis and oncology.
Surrozen’s lead program is advancing in fibrotic disease, where restoring proper Wnt signaling may support the repair of damaged tissues in conditions such as idiopathic pulmonary fibrosis. In parallel, the company has active oncology research efforts aimed at leveraging Wnt pathway agonism to enhance anti‐tumor immunity and improve responses to existing cancer therapies. All of its therapeutic candidates remain in preclinical or early clinical stages, with the company working to characterize efficacy, safety and dosing profiles.
The company was founded in 2017 by a team of experienced biotech entrepreneurs and scientists, including Chief Executive Officer Denny Kim, Ph.D., who brings extensive expertise in antibody engineering and translational research. Surrozen’s leadership team combines backgrounds in immunology, regenerative medicine and drug development, and benefits from a board of directors composed of industry veterans drawn from leading pharmaceutical and biotech firms.
Surrozen collaborates with academic institutions and pharmaceutical partners to accelerate its pipeline and leverage complementary expertise. By focusing on tissue repair and controlled pathway activation, the company aims to address significant unmet medical needs across global markets and create new therapeutic modalities that go beyond traditional small molecules and monoclonal antibodies.
AI Generated. May Contain Errors.
Free SRZNW Stock Alerts